Johnson & Johnson's Imaavy Gets FDA Priority Review for Rare Blood Disorder

Published: 2026-04-27 09:01:27 ET JNJ

Published on 04/27/2026 at 09:01 am EDT

By Adriano Marchese

Johnson & Johnson secured fast-track status for its autoimmune drug Imaavy, accelerating the regulatory timeline for what could become the first approved treatment for warm autoimmune hemolytic anemia.

The pharmaceutical, biotechnology and medical-technologies giant said Monday that Imaavy, also known as nipocalimab, was granted priority review by the Food and Drug Administration.

The status is an accelerated process that shortens the review of a new-drug application when the medicine could offer a major improvement for a serious or life-threatening condition.

Warm autoimmune hemolytic anemia is a rare and serious autoimmune disease in which the body's immune system mistakenly destroys its own red blood cells, causing anemia. Imaavy is designed to target the underlying cause of the disease by reducing circulating immunoglobulin G, including autoantibodies, while preserving critical immune functions, J&J said.

The company said the FDA's decision follows positive results for its Phase 2/3 Energy study that showed patients treated with the drug saw the condition improve.

The drug is being studied across multiple auto- and alloantibody-driven diseases as well, J&J said.

Write to Adriano Marchese at [email protected]

(END) Dow Jones Newswires

04-27-26 0859ET